A Phase 3 interventional study of Ranibizumab in Diabetic Macular Edema, sponsored by Novartis Pharmaceuticals. Completed at 68 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-09-15.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 91 studies testing ranibizumab in Macular Edema — none open to participants now, none under way, none of them phase 3. Ranibizumab · Macular Edema.
Among the 91 studies testing ranibizumab in Macular Edema, this one is the 10th largest by enrollment, is one of 5 that started in 2010, is one of 25 in phase 3, and was the 24th registered.
758 studies on the registry are indexed under Macular Edema; 65 are open to participants now.
Browse Macular Edema studies →None of the 91 studies testing ranibizumab in Macular Edema is open now. The open studies under Macular Edema, anywhere →
Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
91 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 28 · Phase 3 28 · Phase 4 26
First in 2004; this study’s year is marked. 5 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 373 is above the median of 56 across 586 interventional studies indexed under Macular Edema.
Median enrollment 50 across the 91 interventional studies. Of the 65 that completed or were terminated, 39 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
37 of 91 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,721 studies on the registry; 222 are open to participants now.
Of its 586 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
39 studies in Macular Edema by Novartis: none open now, none under way, none of them phase 3. Of 37 finished, 25 (68%) have results posted.
Among the 39 studies in Macular Edema by Novartis, this one is the 8th largest by enrollment of the 36 interventional ones that give a count, is one of 3 that started in 2010, is one of 22 in phase 3, and was the 7th registered.
Novartis’s Macular Edema studies by the year they started, since 2005.
None of the studies under way reaches primary completion within a year.
Among the 91 studies testing ranibizumab in Macular Edema, from their registry updates:
Among Novartis’s 39 in Macular Edema:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to demonstrate that two investigational treatment regimens have the potential to result in a superior visual acuity improvement as compared to a ranibizumab pro re nata (PRN=as needed) treatment regimen.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patient
Ocular
Exclusion Criteria:
Patient Compliance/ Administrative
Ocular medical history
Prior Ocular treatments
Systemic conditions or treatments
Other protocol-defined inclusion/exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
On Day 1, all patients received an intravitreal injection with 0.5 mg ranibizumab and subsequently entered Phase A which comprised of monthly injections. Laser therapy was applied at Day 1. It could then be re-administered according to ETDRS criteria at any visit with 0.5 mg ranibizumab treatment if deemed necessary by the Treating Investigator with a minimal treatment interval between laser treatments of 3 months. Laser therapy was administered ≥ 30 minutes prior to the ranibizumab injection.
Drug: Ranibizumab
Patients received ranibizumab intravitreal injection therapy only.
Drug: Ranibizumab
Patients received ranibizumab intravitreal injection therapy as needed according to signs and symptoms of disease.
Drug: Ranibizumab
Ranibizumab (Lucentis®) was supplied in vials containing a dose of 0.5 mg/0.05 mL in an aqueous solution (pH 5.5) with histidine, trehalose, and polysorbate 20.
Visual Acuity of the Study Eye: Average Change From Baseline to Month 1 Through Month 12
Visual acuity was assessed at every study visit for the study eye using best correction determined from protocol refraction. The BCVA measurements were taken in a sitting position using ETDRS-like VA testing charts at a starting distance of 4 meters.
Time frame: Baseline to Month 12
Visual Acuity of the Study Eye: Average Change From Baseline to Month 1 Through Month 24
Visual acuity was assessed at every study visit for the study eye using best correction determined from protocol refraction. The BCVA measurements were taken in a sitting position using ETDRS-like VA testing charts at a starting distance of 4 meters.
Time frame: Baseline to Month 24
Visual Acuity of the Study Eye: Change From Baseline at Month 12
Visual acuity was assessed at every study visit for the study eye using best correction determined from protocol refraction. The BCVA measurements were taken in a sitting position using ETDRS-like VA testing charts at a starting distance of 4 meters.
Time frame: Baseline and Month 12
Visual Acuity of the Study Eye: Change From Baseline at Month 24
Visual acuity was assessed at every study visit for the study eye using best correction determined from protocol refraction. The BCVA measurements were taken in a sitting position using ETDRS-like VA testing charts at a starting distance of 4 meters.
Time frame: Baseline and Month 24
Visual Acuity of the Study Eye: Categorized Change From Baseline at Month 12
Visual acuity was assessed at every study visit for the study eye using best correction determined from protocol refraction. The BCVA measurements were taken in a sitting position using ETDRS-like VA testing charts at a starting distance of 4 meters.
Time frame: Baseline, Month 12
Visual Acuity of the Study Eye: Categorized Change From Baseline at Month 24
Visual acuity was assessed at every study visit for the study eye using best correction determined from protocol refraction. The BCVA measurements were taken in a sitting position using ETDRS-like VA testing charts at a starting distance of 4 meters.
Time frame: Baseline, 24 month
Central Subfield Thickness of the Study Eye: Percent Change From Baseline at Month 12
High Resolution OCT was performed at every study visit by Spectral Domain OCT (if not available Time Domain OCT was acceptable) and the images were transferred to a digital video disc. These assessments were performed by trained and adequately qualified experts at the sites and prior to any study drug administration. CSFT is the average retinal thickness of the circular area with 1 mm diameter around the foveal center.
Time frame: Baseline, Month 12
Central Subfield Thickness of the Study Eye: Percent Change From Baseline at Month 24
High Resolution OCT was performed at every study visit by Spectral Domain OCT (if not available Time Domain OCT was acceptable) and the images were transferred to a digital video disc. These assessments were performed by trained and adequately qualified experts at the sites and prior to any study drug administration. CSFT is the average retinal thickness of the circular area with 1 mm diameter around the foveal center.
Time frame: Baseline and 24 month
Visual Functioning Questionnaire (VFQ-25) Change From Baseline in Total Score at Month 12 and Month 24
The National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) was used to measure the influence of visual disability and symptoms on general health. The 12 subscales in the VFQ-25 are general health, general vision, ocular pain, near activities, distance activities, social function, mental health, role difficulties, dependency, driving, color vision, and peripheral vision. For each, the patient was asked to rate their condition on a scale of 1-5 or 1-6, where a low number reflects a better outcome. Each response was recoded per the scoring rules outlined in the National Eye Institute (NEI) VFQ-25 Scoring Algorithm. Under this scoring algorithm , the recoded values range between 0 and 100 and a high score means a better functioning
Time frame: Baseline, Month 12 and Month 24
EuroQoL (EQ-5D) Thermometer Score: Change From Baseline at Month 12 and Month 24
The Euro Quality of Life Questionnaire (EQ-5D) is an indirect utility questionnaire. It is a standardized instrument was utilized to measure health outcomes related to 5 dimensions, namely: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The possible range for each dimension was 1 to 3, where 1= "no problems", 2="some problems" and 3="extreme problems" . A composite health index was then defined by combining the levels for each dimension. Overall, 243 health states are possible. For each health state, the EuroQol group has assigned a utility value typically between 0 and 1 with lower scores representing a higher level of dysfunction
Time frame: Baseline, Month 12 and Month 24
A total of 373 patients with macular edema and visual impairment secondary to DME were enrolled. A total of 372 patients were randomized. One patient was excluded from all analyses due to administrative problems
| Milestone | TE Ranibizumad 0.5 mg and Laser | TE Ranibizumab 0.5 mg Alone | PRN Ranibizumab 0.5 mg |
|---|---|---|---|
| Started | 121 | 128 | 123 |
| Safety set | 126 | 126 | 118 |
| Completed | 107 | 117 | 108 |
| Not completed | 14 | 11 | 15 |
| Withdrew: Protocol violation | 0 | 0 | 1 |
| Withdrew: Death | 2 | 4 | 1 |
| Withdrew: Lost to follow-up | 4 | 0 | 2 |
| Withdrew: Withdrawal by subject | 1 | 5 | 6 |
| Withdrew: Abnormal test result | 1 | 0 | 0 |
| Withdrew: Adverse event | 6 | 2 | 5 |
Visual acuity was assessed at every study visit for the study eye using best correction determined from protocol refraction. The BCVA measurements were taken in a sitting position using ETDRS-like VA testing charts at a starting distance of 4 meters.
| Letters | TE Ranibizumad 0.5 mg and Laser | TE Ranibizumab 0.5 mg Alone | PRN Ranibizumab 0.5 mg |
|---|---|---|---|
| Baseline | 62.3 ± 11.50 | 64.1 ± 10.52 | 65.1 ± 10.08 |
| Average Month 1 to Month 12 | 68.25 ± 11.057 | 70.28 ± 10.284 | 71.32 ± 9.984 |
| Average Change from Baseline | 5.91 ± 5.532 | 6.14 ± 5.717 | 6.20 ± 6.005 |
Visual acuity was assessed at every study visit for the study eye using best correction determined from protocol refraction. The BCVA measurements were taken in a sitting position using ETDRS-like VA testing charts at a starting distance of 4 meters.
| Letters | TE Ranibizumad 0.5 mg and Laser | TE Ranibizumab 0.5 mg Alone | PRN Ranibizumab 0.5 mg |
|---|---|---|---|
| Baseline | 62.3 ± 11.50 | 64.1 ± 10.52 | 65.1 ± 10.08 |
| Average Month 1 to Month 24 | 69.12 ± 11.261 | 70.72 ± 10.924 | 72.09 ± 10.141 |
| Average Change from Baseline | 6.78 ± 5.986 | 6.58 ± 7.070 | 6.97 ± 6.430 |
Visual acuity was assessed at every study visit for the study eye using best correction determined from protocol refraction. The BCVA measurements were taken in a sitting position using ETDRS-like VA testing charts at a starting distance of 4 meters.
| Letters | TE Ranibizumad 0.5 mg and Laser | TE Ranibizumab 0.5 mg Alone | PRN Ranibizumab 0.5 mg |
|---|---|---|---|
| Baseline | 62.3 ± 11.50 | 65.1 ± 10.52 | 65.1 ± 10.08 |
| Month 12 | 69.13 ± 11.945 | 70.93 ± 11.742 | 72.56 ± 11.592 |
| Change from Baseline | 6.79 ± 6.999 | 6.80 ± 8.726 | 7.44 ± 8.457 |
Visual acuity was assessed at every study visit for the study eye using best correction determined from protocol refraction. The BCVA measurements were taken in a sitting position using ETDRS-like VA testing charts at a starting distance of 4 meters.
| Letters | TE Ranibizumad 0.5 mg and Laser | TE Ranibizumab 0.5 mg Alone | PRN Ranibizumab 0.5 mg |
|---|---|---|---|
| Baseline | 62.3 ± 11.50 | 64.1 ± 10.52 | 65.1 ± 10.08 |
| Month 24 | 70.64 ± 12.315 | 70.62 ± 13.481 | 73.18 ± 11.872 |
| Change from Baseline | 8.30 ± 8.129 | 6.49 ± 10.854 | 8.06 ± 8.462 |
Visual acuity was assessed at every study visit for the study eye using best correction determined from protocol refraction. The BCVA measurements were taken in a sitting position using ETDRS-like VA testing charts at a starting distance of 4 meters.
| Percentage of patients | TE Ranibizumad 0.5 mg and Laser | TE Ranibizumab 0.5 mg Alone | PRN Ranibizumab 0.5 mg |
|---|---|---|---|
| Gain of >= 1 letter | 82.9 | 84.8 | 83.8 |
| Gain of >= 5 letters | 59.0 | 60.8 | 70.1 |
| Gain of >= 10 letters | 32.5 | 42.4 | 39.3 |
| Gain of >= 15 letters | 19.7 | 30.4 | 26.5 |
| Loss of >= 5 letters | 3.4 | 4.0 | 3.4 |
| Loss of >= 10 letters | 0.0 | 2.4 | 0.9 |
| Loss of >= 15 letters | 0.0 | 1.6 | 0.9 |
Visual acuity was assessed at every study visit for the study eye using best correction determined from protocol refraction. The BCVA measurements were taken in a sitting position using ETDRS-like VA testing charts at a starting distance of 4 meters.
| Percentage of pateints | TE Ranibizumad 0.5 mg and Laser | TE Ranibizumab 0.5 mg Alone | PRN Ranibizumab 0.5 mg |
|---|---|---|---|
| Gain of >= 1 letter | 87.2 | 84.0 | 90.6 |
| Gain of >= 5 letters | 69.2 | 62.4 | 76.1 |
| Gain of >= 10 letters | 43.6 | 40.8 | 45.3 |
| Gain of >= 15 letters | 25.6 | 28.0 | 30.8 |
| Loss of >= 5 letters | 4.3 | 8.0 | 5.1 |
| Loss of >= 10 letters | 2.6 | 7.2 | 3.4 |
| Loss of >= 15 letters | 0.9 | 4.0 | 2.6 |
High Resolution OCT was performed at every study visit by Spectral Domain OCT (if not available Time Domain OCT was acceptable) and the images were transferred to a digital video disc. These assessments were performed by trained and adequately qualified experts at the sites and prior to any study drug administration. CSFT is the average retinal thickness of the circular area with 1 mm diameter around the foveal center.
| Percent Change | TE Ranibizumad 0.5 mg and Laser | TE Ranibizumab 0.5 mg Alone | PRN Ranibizumab 0.5 mg |
|---|---|---|---|
| Central Subfield Thickness of the Study Eye: Percent Change From Baseline at Month 12 | -27.09 ± 22.992 | -24.35 ± 22.027 | -23.16 ± 22.362 |
High Resolution OCT was performed at every study visit by Spectral Domain OCT (if not available Time Domain OCT was acceptable) and the images were transferred to a digital video disc. These assessments were performed by trained and adequately qualified experts at the sites and prior to any study drug administration. CSFT is the average retinal thickness of the circular area with 1 mm diameter around the foveal center.
| Percent Change | TE Ranibizumad 0.5 mg and Laser | TE Ranibizumab 0.5 mg Alone | PRN Ranibizumab 0.5 mg |
|---|---|---|---|
| Central Subfield Thickness of the Study Eye: Percent Change From Baseline at Month 24 | -32.03 ± 25.628 | -24.98 ± 26.414 | -24.97 ± 26.678 |
The National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) was used to measure the influence of visual disability and symptoms on general health. The 12 subscales in the VFQ-25 are general health, general vision, ocular pain, near activities, distance activities, social function, mental health, role difficulties, dependency, driving, color vision, and peripheral vision. For each, the patient was asked to rate their condition on a scale of 1-5 or 1-6, where a low number reflects a better outcome. Each response was recoded per the scoring rules outlined in the National Eye Institute (NEI) VFQ-25 Scoring Algorithm. Under this scoring algorithm , the recoded values range between 0 and 100 and a high score means a better functioning
| Score on a scale | TE Ranibizumad 0.5 mg and Laser | TE Ranibizumab 0.5 mg Alone | PRN Ranibizumab 0.5 mg |
|---|---|---|---|
| Baseline (n=116,122,114) | 75.32 ± 17.317 | 75.47 ± 17.105 | 77.07 ± 18.581 |
| Change from baseline at Month 12 (n=116,122,114) | 4.60 ± 10.905 | 3.95 ± 10.941 | 5.41 ± 12.063 |
| Change from baseline at month 24 (n=116,122,114) | 4.06 ± 11.859 | 2.31 ± 13.270 | 5.96 ± 12.389 |
The Euro Quality of Life Questionnaire (EQ-5D) is an indirect utility questionnaire. It is a standardized instrument was utilized to measure health outcomes related to 5 dimensions, namely: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The possible range for each dimension was 1 to 3, where 1= "no problems", 2="some problems" and 3="extreme problems" . A composite health index was then defined by combining the levels for each dimension. Overall, 243 health states are possible. For each health state, the EuroQol group has assigned a utility value typically between 0 and 1 with lower scores representing a higher level of dysfunction
| Score on a scale | TE Ranibizumad 0.5 mg and Laser | TE Ranibizumab 0.5 mg Alone | PRN Ranibizumab 0.5 mg |
|---|---|---|---|
| Baseline | 71.4 ± 17.36 | 70.7 ± 16.10 | 72.2 ± 13.24 |
| Change from Baseline at Month 12 (n=115,123,113) | 0.47 ± 16.487 | 0.91 ± 13.422 | 2.52 ± 14.431 |
| Change from Baseline at Month 24 (n=115,123,113) | 1.35 ± 17.464 | 0.11 ± 14.755 | 1.98 ± 14.812 |
Non-serious events are listed at a 1.5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| TE Ranibizumab 0.5 mg and Laser | — | 34/126 (27%) | 98/126 (77.8%) |
| TE Ranibizumab 0.5 mg Alone | — | 29/126 (23%) | 101/126 (80.2%) |
| PRN Ranibizumab 0.5 mg | — | 26/118 (22%) | 78/118 (66.1%) |
| Event | TE Ranibizumab 0.5 mg and Laser | TE Ranibizumab 0.5 mg Alone | PRN Ranibizumab 0.5 mg |
|---|---|---|---|
| Myocardial infarctionCardiac disorders | 4/126 | 1/126 | 1/118 |
| Cerebrovascular accidentNervous system disorders | 1/126 | 2/126 | 3/118 |
| PneumoniaInfections and infestations | 3/126 | 1/126 | 0/118 |
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/126 | 0/126 | 2/118 |
| Acute myocardial infarctionCardiac disorders | 0/126 | 2/126 | 0/118 |
| Atrial fibrillationCardiac disorders | 0/126 | 2/126 | 0/118 |
| Myocardial ischaemiaCardiac disorders | 0/126 | 2/126 | 1/118 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 0/126 | 2/126 | 0/118 |
| Skin ulcerSkin and subcutaneous tissue disorders | 0/126 | 2/126 | 0/118 |
| AnaemiaBlood and lymphatic system disorders | 0/126 | 0/126 | 1/118 |
| Event | TE Ranibizumab 0.5 mg and Laser | TE Ranibizumab 0.5 mg Alone | PRN Ranibizumab 0.5 mg |
|---|---|---|---|
| HypertensionVascular disorders | 19/126 | 17/126 | 8/118 |
| Conjunctival haemorrhage (Study eye)Eye disorders | 5/126 | 11/126 | 6/118 |
| BronchitisInfections and infestations | 11/126 | 1/126 | 5/118 |
| NasopharyngitisInfections and infestations | 11/126 | 10/126 | 8/118 |
| InfluenzaInfections and infestations | 9/126 | 10/126 | 8/118 |
| Urinary tract infectionInfections and infestations | 9/126 | 10/126 | 5/118 |
| Back painMusculoskeletal and connective tissue disorders | 8/126 | 10/126 | 3/118 |
| Eye pain (Study eye)Eye disorders | 8/126 | 7/126 | 3/118 |
| Vitreous haemorrhage (Study eye)Eye disorders | 8/126 | 2/126 | 0/118 |
| Cataract (Study eye)Eye disorders | 5/126 | 7/126 | 7/118 |
The Randomized Set comprised all randomized patients, ie those given a randomization number.
| Age, Continuous(Years) | TE Ranibizumad 0.5 mg and Laser | TE Ranibizumab 0.5 mg Alone | PRN Ranibizumab 0.5 mg | Total |
|---|---|---|---|---|
| Mean | 63.7 ± 9.07 | 63.0 ± 9.83 | 64.5 ± 9.66 | 63.7 ± 9.53 |
| Sex: Female, Male(Participants) | TE Ranibizumad 0.5 mg and Laser | TE Ranibizumab 0.5 mg Alone | PRN Ranibizumab 0.5 mg | Total |
|---|---|---|---|---|
| Female | 43 | 51 | 46 | 140 |
| Male | 78 | 77 | 77 | 232 |
The record gives a start of Sep 2010, a primary completion of Apr 2013 and a completion of Apr 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2014, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ranibizumab